Clinical trials: Partial Onset Seizures
Epilepsy
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
- Trial name
- NCT00464269
- Testing
- Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 400 people
- Sponsor
- UCB Pharma
Refractory Partial Onset Seizures
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301.
- Trial name
- NCT00448539
- Testing
- Rufinamide
- Where
- 27 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eisai Inc.
Focal Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- Trial name
- RISE 2 (NCT06132893)
- Testing
- BHV-7000
- Where
- 104 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- Biohaven Therapeutics Ltd.
Focal Epilepsy, Generalized Epilepsy
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
Background: Epilepsy is a chronic neurological disease which affects approximately 70,000 patients in Hong Kong and 50 billion people worldwide. Among these patients one-third remained unresponsive to antiepileptic agents.
- Conditions
- Focal Epilepsy, Generalized Epilepsy, Partial Seizures, Simple
- Trial name
- NCT03457961
- Testing
- Perampanel
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Epilepsy
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
Study to evaluate the efficacy of Lacosamide (LCM) administered in addition to 1 to ≤3 other Anti-Epileptic Drugs in subjects with epilepsy ≥4 years to <17 years of age who currently have uncontrolled partial onset seizures.
- Trial name
- NCT01921205
- Testing
- Lacosamide
- Where
- 118 sites in United States, Argentina and 26 more
- Volunteers
- 404 people
- Sponsor
- UCB Pharma
Partial Epilepsy
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures.
- Trial name
- NCT02535091
- Testing
- YKP3089
- Where
- 121 sites in United States, Argentina and 15 more
- Volunteers
- 1,345 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Epilepsies, Partial
A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure
The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy…
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00230698
- Testing
- topiramate
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures
A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures [including secondarily generalized seizures]) (age 4 years or older) or…
- Trial name
- NCT06657378
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource…
- Trial name
- NCT01728077
- Testing
- Brivaracetam
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 26 people
- Sponsor
- UCB Pharma SA
Epilepsy With POS With or Without Secondary Generalization
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard…
- Trial name
- BASE (NCT02687711)
- Where
- 44 sites in Denmark, Germany and 7 more
- Volunteers
- 544 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
This is a Phase III, multinational, open-label, non-controlled study with subjects under treatment in the double-blind BIA-2093-311 study (NCT01162460).
- Trial name
- NCT02484001
- Testing
- ESL 800 mg, ESL 1200 mg, ESL 1600 mg
- Volunteers
- 206 people
- Sponsor
- Bial - Portela C S.A.
Partial Onset Seizures
Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures
This study is designed to provide long term safety data of TRI476 in children with inadequately-controlled partial seizures. This study is conducted in patients who complete the core study CTRI476B1301.
- Trial name
- NCT01051193
- Testing
- Oxcarbazepine
- Where
- 24 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Nobelpharma
Focal-Onset Seizures
Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice.
- Trial name
- ENGAGE (NCT07793396)
- Testing
- Eslicarbazepine acetate
- Where
- Pakistan
- Volunteers
- 1,500 people
- Sponsor
- King Edward Medical University
Epilepsy, Partial
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial…
- Trial name
- NCT00105040
- Testing
- Levetiracetam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- UCB Pharma